Do analysts recommend ADCT or TAOX?

ADC Therapeutics currently has a consensus price target of $6.25, indicating a potential upside of 492.98%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe ADC Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADC Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.33 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media favor ADCT or TAOX?

In the previous week, ADC Therapeutics had 1 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.28 beat ADC Therapeutics' score of -0.67 indicating that Synaptogenix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADC Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Synaptogenix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate PLYX or TAOX?

Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 321.94%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Polaryx Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Polaryx Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher valuation and earnings, PLYX or TAOX?

Polaryx Therapeutics has higher earnings, but lower revenue than Synaptogenix. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Polaryx Therapeutics N/A N/A N/A N/A N/A Synaptogenix $300K 90.14 -$28.74M -$13.28 N/A

Is PLYX or TAOX more profitable?

Polaryx Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Polaryx Therapeutics N/A N/A N/A Synaptogenix N/A -163.40% -133.47%

Do analysts recommend TAOX or CGTX?

Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 175.48%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cognition Therapeutics 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is TAOX or CGTX more profitable?

Cognition Therapeutics' return on equity of -72.68% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% Cognition Therapeutics N/A -72.68% -53.07%

Does the media prefer TAOX or CGTX?

In the previous week, Synaptogenix and Synaptogenix both had 2 articles in the media. Synaptogenix's average media sentiment score of 1.28 beat Cognition Therapeutics' score of 0.94 indicating that Synaptogenix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synaptogenix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cognition Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer PYXS or TAOX?

Pyxis Oncology presently has a consensus target price of $6.83, indicating a potential upside of 288.26%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Pyxis Oncology is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pyxis Oncology 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.63 Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is PYXS or TAOX more profitable?

Pyxis Oncology's return on equity of -135.60% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Pyxis Oncology N/A -135.60% -85.00% Synaptogenix N/A -163.40% -133.47%

Does the media refer more to PYXS or TAOX?

In the previous week, Pyxis Oncology and Pyxis Oncology both had 2 articles in the media. Pyxis Oncology's average media sentiment score of 1.68 beat Synaptogenix's score of 1.28 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Synaptogenix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate TAOX or ENGN?

enGene has a consensus price target of $12.68, indicating a potential upside of 682.83%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Synaptogenix. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Synaptogenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 enGene 1 Sell rating(s) 9 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.21

Which has better earnings and valuation, TAOX or ENGN?

Synaptogenix has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Synaptogenix $300K 90.14 -$28.74M -$13.28 N/A enGene N/A N/A -$117.30M -$2.25 N/A

Is TAOX or ENGN more profitable?

enGene's return on equity of -55.83% beat Synaptogenix's return on equity. Company Net Margins Return on Equity Return on Assets Synaptogenix N/A -163.40% -133.47% enGene N/A -55.83% -45.74%

Does the media prefer TAOX or ENGN?

In the previous week, enGene had 10 more articles in the media than Synaptogenix. MarketBeat recorded 12 mentions for enGene and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.28 beat enGene's score of 0.08 indicating that Synaptogenix is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Synaptogenix 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive enGene 0 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Synaptogenix (TAOX) Competitors

$3.62 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$3.64 +0.02 (+0.69%)

As of 06/12/2026 07:42 PM Eastern

Compare

TAOX vs. ADCT, PLYX, CGTX, PYXS, and ENGN

Should you buy Synaptogenix stock or one of its competitors? MarketBeat compares Synaptogenix with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Synaptogenix include ADC Therapeutics (ADCT), Polaryx Therapeutics (PLYX), Cognition Therapeutics (CGTX), Pyxis Oncology (PYXS), and enGene (ENGN). These companies are all part of the "pharmaceutical products" industry.

How does Synaptogenix compare to ADC Therapeutics?

ADC Therapeutics (NYSE:ADCT) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

In the previous week, ADC Therapeutics had 1 more articles in the media than Synaptogenix. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.28 beat ADC Therapeutics' score of -0.67 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Synaptogenix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ADC Therapeutics currently has a consensus price target of $6.25, indicating a potential upside of 492.98%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe ADC Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ADC Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ADC Therapeutics has a beta of 1.77, meaning that its stock price is 77% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Synaptogenix has a net margin of 0.00% compared to ADC Therapeutics' net margin of -173.02%. ADC Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ADC Therapeutics	-173.02%	N/A	-44.70%
Synaptogenix	N/A	-163.40%	-133.47%

41.1% of ADC Therapeutics shares are held by institutional investors. Comparatively, 10.3% of Synaptogenix shares are held by institutional investors. 5.4% of ADC Therapeutics shares are held by company insiders. Comparatively, 2.7% of Synaptogenix shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Synaptogenix has lower revenue, but higher earnings than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ADC Therapeutics	$81.36M	1.65	-$142.62M	-$1.05	N/A
Synaptogenix	$300K	90.14	-$28.74M	-$13.28	N/A

Summary

ADC Therapeutics beats Synaptogenix on 11 of the 16 factors compared between the two stocks.

How does Synaptogenix compare to Polaryx Therapeutics?

Polaryx Therapeutics (NASDAQ:PLYX) and Synaptogenix (NASDAQ:TAOX) are both small-cap manufacturing companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

10.3% of Synaptogenix shares are owned by institutional investors. 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Polaryx Therapeutics and Polaryx Therapeutics both had 2 articles in the media. Synaptogenix's average media sentiment score of 1.28 beat Polaryx Therapeutics' score of 0.44 indicating that Synaptogenix is being referred to more favorably in the news media.

Company	Overall Sentiment
Polaryx Therapeutics	Neutral
Synaptogenix	Positive

Polaryx Therapeutics' return on equity of 0.00% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Polaryx Therapeutics	N/A	N/A	N/A
Synaptogenix	N/A	-163.40%	-133.47%

Polaryx Therapeutics has higher earnings, but lower revenue than Synaptogenix.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A
Synaptogenix	$300K	90.14	-$28.74M	-$13.28	N/A

Polaryx Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 321.94%. Given Polaryx Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Polaryx Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Polaryx Therapeutics beats Synaptogenix on 5 of the 9 factors compared between the two stocks.

How does Synaptogenix compare to Cognition Therapeutics?

Synaptogenix (NASDAQ:TAOX) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, institutional ownership, valuation, dividends, analyst recommendations, earnings and profitability.

Cognition Therapeutics has a consensus price target of $3.33, indicating a potential upside of 175.48%. Given Cognition Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Cognition Therapeutics is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Cognition Therapeutics' return on equity of -72.68% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
Cognition Therapeutics	N/A	-72.68%	-53.07%

Cognition Therapeutics has lower revenue, but higher earnings than Synaptogenix. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	90.14	-$28.74M	-$13.28	N/A
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A

Synaptogenix has a beta of 1.41, indicating that its stock price is 41% more volatile than the broader market. Comparatively, Cognition Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the broader market.

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 11.1% of Cognition Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Synaptogenix and Synaptogenix both had 2 articles in the media. Synaptogenix's average media sentiment score of 1.28 beat Cognition Therapeutics' score of 0.94 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synaptogenix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cognition Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Cognition Therapeutics beats Synaptogenix on 10 of the 13 factors compared between the two stocks.

How does Synaptogenix compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Synaptogenix (NASDAQ:TAOX) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, media sentiment, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Pyxis Oncology has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, Synaptogenix has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market.

Pyxis Oncology presently has a consensus target price of $6.83, indicating a potential upside of 288.26%. Given Pyxis Oncology's stronger consensus rating and higher probable upside, equities analysts plainly believe Pyxis Oncology is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Synaptogenix has lower revenue, but higher earnings than Pyxis Oncology. Pyxis Oncology is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	8.04	-$79.62M	-$1.31	N/A
Synaptogenix	$300K	90.14	-$28.74M	-$13.28	N/A

In the previous week, Pyxis Oncology and Pyxis Oncology both had 2 articles in the media. Pyxis Oncology's average media sentiment score of 1.68 beat Synaptogenix's score of 1.28 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Synaptogenix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology's return on equity of -135.60% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Synaptogenix	N/A	-163.40%	-133.47%

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 10.3% of Synaptogenix shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 2.7% of Synaptogenix shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Pyxis Oncology beats Synaptogenix on 11 of the 14 factors compared between the two stocks.

How does Synaptogenix compare to enGene?

Synaptogenix (NASDAQ:TAOX) and enGene (NASDAQ:ENGN) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, earnings, analyst recommendations, risk, valuation and media sentiment.

In the previous week, enGene had 10 more articles in the media than Synaptogenix. MarketBeat recorded 12 mentions for enGene and 2 mentions for Synaptogenix. Synaptogenix's average media sentiment score of 1.28 beat enGene's score of 0.08 indicating that Synaptogenix is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Synaptogenix	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
enGene	0 Very Positive mention(s)	1 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Synaptogenix has a beta of 1.41, suggesting that its stock price is 41% more volatile than the broader market. Comparatively, enGene has a beta of -0.29, suggesting that its stock price is 129% less volatile than the broader market.

enGene's return on equity of -55.83% beat Synaptogenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Synaptogenix	N/A	-163.40%	-133.47%
enGene	N/A	-55.83%	-45.74%

enGene has a consensus price target of $12.68, indicating a potential upside of 682.83%. Given enGene's stronger consensus rating and higher probable upside, analysts plainly believe enGene is more favorable than Synaptogenix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Synaptogenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
enGene	1 Sell rating(s)	9 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.21

10.3% of Synaptogenix shares are held by institutional investors. Comparatively, 64.2% of enGene shares are held by institutional investors. 2.7% of Synaptogenix shares are held by insiders. Comparatively, 10.5% of enGene shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Synaptogenix has higher revenue and earnings than enGene. enGene is trading at a lower price-to-earnings ratio than Synaptogenix, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Synaptogenix	$300K	90.14	-$28.74M	-$13.28	N/A
enGene	N/A	N/A	-$117.30M	-$2.25	N/A

Summary

enGene beats Synaptogenix on 9 of the 14 factors compared between the two stocks.

Get Synaptogenix News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TAOX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TAOX vs. The Competition

Export

Metric	Synaptogenix	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$27.04M	$979.54M	$4.29B	$12.05B
Dividend Yield	N/A	4.84%	10.25%	5.66%
P/E Ratio	-0.27	1.45	22.29	24.42
Price / Sales	90.14	120.49	159.54	111.24
Price / Cash	N/A	20.06	40.19	37.92
Price / Book	1.28	7.85	26.92	6.82
Net Income	-$28.74M	-$4.88M	$116.61M	$337.56M
7 Day Performance	-5.97%	0.64%	0.25%	1.17%
1 Month Performance	-30.65%	-0.16%	0.25%	3.16%
1 Year Performance	N/A	47.51%	14.25%	30.58%

Synaptogenix Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TAOX Synaptogenix	0.7478 of 5 stars	$3.62 flat	N/A	N/A	$27.04M	$300K	N/A	4	Positive News Gap Up
ADCT ADC Therapeutics	2.3306 of 5 stars	$0.92 -11.0%	$6.25 +581.6%	-70.8%	$116.51M	$79.18M	N/A	310
PLYX Polaryx Therapeutics	4.0526 of 5 stars	$2.45 +4.9%	$10.00 +309.0%	N/A	$114.99M	N/A	N/A	11	Short Interest Increase Gap Up
CGTX Cognition Therapeutics	4.0571 of 5 stars	$1.27 -1.9%	$3.33 +163.5%	+305.6%	$113.22M	N/A	N/A	20	Positive News Gap Down
PYXS Pyxis Oncology	3.6362 of 5 stars	$1.77 -0.8%	$6.83 +287.2%	+46.7%	$111.81M	$13.86M	N/A	60	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TAOX) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Synaptogenix (TAOX) Competitors

TAOX vs. ADCT, PLYX, CGTX, PYXS, and ENGN

How does Synaptogenix compare to ADC Therapeutics?

Summary

How does Synaptogenix compare to Polaryx Therapeutics?

Summary

How does Synaptogenix compare to Cognition Therapeutics?

Summary

How does Synaptogenix compare to Pyxis Oncology?

Summary

How does Synaptogenix compare to enGene?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Synaptogenix (TAOX) Competitors

TAOX vs. ADCT, PLYX, CGTX, PYXS, and ENGN

How does Synaptogenix compare to ADC Therapeutics?

Does the media favor ADCT or TAOX?

Do analysts recommend ADCT or TAOX?

Which has more volatility and risk, ADCT or TAOX?

Is ADCT or TAOX more profitable?

Do insiders & institutionals believe in ADCT or TAOX?

Which has stronger valuation and earnings, ADCT or TAOX?

Summary

How does Synaptogenix compare to Polaryx Therapeutics?

Do institutionals and insiders believe in PLYX or TAOX?

Does the media prefer PLYX or TAOX?

Is PLYX or TAOX more profitable?

Which has higher valuation and earnings, PLYX or TAOX?

Do analysts rate PLYX or TAOX?

Summary

How does Synaptogenix compare to Cognition Therapeutics?

Do analysts recommend TAOX or CGTX?

Is TAOX or CGTX more profitable?

Which has stronger earnings and valuation, TAOX or CGTX?

Which has more volatility & risk, TAOX or CGTX?

Do institutionals & insiders believe in TAOX or CGTX?

Does the media prefer TAOX or CGTX?

Summary

How does Synaptogenix compare to Pyxis Oncology?

Which has more volatility and risk, PYXS or TAOX?

Do analysts prefer PYXS or TAOX?

Which has preferable valuation and earnings, PYXS or TAOX?

Does the media refer more to PYXS or TAOX?

Is PYXS or TAOX more profitable?

Do institutionals and insiders believe in PYXS or TAOX?

Summary

How does Synaptogenix compare to enGene?

Does the media prefer TAOX or ENGN?

Which has more risk and volatility, TAOX or ENGN?

Is TAOX or ENGN more profitable?

Do analysts rate TAOX or ENGN?

Do insiders and institutionals believe in TAOX or ENGN?

Which has better earnings and valuation, TAOX or ENGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TAOX vs. The Competition

Synaptogenix Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools